SOURCE: Stentys

April 05, 2007 10:40 ET

Stentys Appoints Scientific Advisory Board

Company Is Positioning Industry's First Next-Generation Dedicated Stent for Treatment of Blocked Coronary Artery Bifurcations as Simple and Effective as a Conventional Stenting Procedure

PARIS -- (MARKET WIRE) -- April 5, 2007 --

"We are on schedule to begin first-in-man studies by mid-year, and
therefore the creation of such a prominent Scientific Advisory Board is an
important step forward for Stentys."
                           Gonzague Issenmann, Co-Founder and CEO, Stentys
Stentys ( announced today that it has appointed a Scientific Advisory Board (SAB) that includes some of the most prominent names in cardiology. Stentys is the first company to develop the next-generation of dedicated drug-eluting stents for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.

The Stentys Scientific Advisory Board will include: Maurice Buchbinder, M.D., director of interventional cardiology and co-director of the cardiac catheterization lab at Scripps Memorial Hospital, La Jolla, Calif.; Eberhard Grube, M.D., chief of cardiology and angiology at the Helios Herzzentrum Heart Center, Seigburg, Germany, and a consulting professor of medicine at Stanford University; Jean-Claude Laborde, M.D., co-director of the interventional cardiology unit at Clinique Pasteur, Toulouse, France; Thierry Lefevre, M.D., head of interventional cardiology and research at the Institut Cardiovasculaire Paris Sud at Institut Hosptalier Jacques Cartier, Massy, France; and Patrick W. Serruys, M.D., chief of interventional cardiology at the Thoraxcenter-Erasmus University, Rotterdam.

"We are extremely proud to be associated with these outstanding interventional cardiologists, whom we expect will play a crucial role in helping Stentys make treatment of blocked coronary artery bifurcations as simple and effective as a conventional stenting procedure," said Stentys' CEO and co-founder, Gonzague Issenmann.

Coronary artery disease is caused by fatty lesions that narrow the coronary artery's inside diameter (stenosis), consequently reducing the blood flow and depriving the heart muscle of oxygen. The dramatic consequence of this blockage is an often lethal myocardial infarction. Bifurcation is the area where one main vessel branches out into two smaller vessels, one being the continuation of the main vessel, and the other often referred to as the side branch. Narrowings at a bifurcation site are quite common. Indeed, 18 percent of percutaneous coronary interventions involve a bifurcation stenosis. Of those, restenosis (re-occurrence of the blockage) occurs in 20-25 percent of bifurcations treated with drug-eluting stents (DES).

The patent-pending innovation of Stentys' bifurcated stent is that the stent-opening for the side branch can be created anywhere in the stent after it is implanted in the vessel. In short, the procedure's success is independent from accurate positioning. The Stentys procedure is performed in three simple steps: (1) Stentys is implanted in the main vessel with an approximate positioning, like a standard stent; (2) the cardiologist chooses the optimal location for the side branch opening by inserting a balloon through the stent mesh, which is a cath lab-standard procedure; and, (3) the balloon inflation disconnects the mesh and creates the opening -- the Stentys approach allows the in situ modeling of the stent to fit the patient's unique arterial anatomy.

Based in Paris, Stentys intends to make treatment of blocked coronary artery bifurcations as simple and effective as a regular stenting procedure.

Contact Information

  • Contact:
    Ronald Trahan, APR
    Ronald Trahan Associates Inc.
    508-359-4005, x108